's Chart of the Day - SurModics
Jim Van Meerten - - Thu Jul 26, 4:27PM CDT
Related Stocks
 SRDX - Surmodics Inc

The Barchart Chart of the Day belongs to SurModics (SRDX). I found he medical products stocks by using Barchart to sort today's 5 Day Gainers list first by the highest Weighted Alpha, then by technical buy signals of 80% or more. Since the Trend Spotter signaled a buy in 5/2 the stock gained 60.08%.

SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.

SRDXBarchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report.

Barchart technical indicators:

  • 96% technical buy signals
  • 154.77+ Weighted Alpha
  • 128.81% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 12 new highs and up 12.24% in the last month
  • Relative Strength Index 77.13%
  • Technical support level at 60.98
  • Recently traded at 62.35 with a 50 day moving average of 54.62

Fundamental factors:

  • Market Cap $822 million
  • P/E 138.07
  • Revenue expected to grow 5.00% this year and another 14.60% next year
  • Earnings estimated to increase 187.50% next year and continue to compound at an annual rate of 15.00% for the next 5 years
  • Wall Street analysts have 2 strong buy and 1 buy recommendation in place on the stock